Enhanced Polygala Extract-Based Systems for ADHD Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses novel systems, methods, and compositions that improve the efficacy, safety, and convenience of Polygala extract-based treatments for attention-deficit hyperactivity disorder (ADHD).
Background and Problem Solved
The original patent disclosed the use of Radix Polygalae extract for treating ADHD. However, it had limitations in terms of bioavailability, side effects, and efficacy. The present inventive concept addresses these limitations by introducing controlled release delivery mechanisms, synergistic combinations with omega-3 fatty acids, liposomal formulations, and wearable devices for monitoring efficacy.
Detailed Description of the Inventive Concept
The inventive concept encompasses five key aspects: (1) a system for controlled release of the Polygala extract over a prolonged period, enhancing bioavailability and reducing side effects; (2) a method for combining the extract with a cognitive training program to improve attention and working memory; (3) a composition featuring a synergistic amount of omega-3 fatty acids to enhance therapeutic effects; (4) a liposomal formulation to reduce gastrointestinal side effects; and (5) a wearable device-based system for monitoring efficacy and correlating it with the subject's response to the extract.
Novelty and Inventive Step
The new claims introduce novel and non-obvious improvements over the original patent, including controlled release delivery, synergistic combinations, liposomal formulations, and wearable device-based monitoring. These innovations address the limitations of the original patent, providing a more effective, safer, and more convenient treatment option for ADHD.
Alternative Embodiments and Variations
Alternative embodiments may include varying the composition of the Polygala extract, using different delivery mechanisms, or incorporating additional cognitive training programs. Variations may also include adapting the wearable device-based system for monitoring other neurological disorders.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the growing market for ADHD treatments. The enhanced systems and methods disclosed herein may attract partnerships with major pharmaceutical companies, healthcare providers, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/69 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K9/485 |
| A | A61 | A61K9/4825 |
| A | A61 | A61K9/4858 |
| A | A61 | A61K47/02 |
| A | A61 | A61K47/12 |
| A | A61 | A61P25/28 |
| A | A61 | A61K2236/333 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions and treatment methods for neurological disorders, specifically ADHD therapeutics, involving botanical extracts, drug delivery systems, and neurological monitoring technologies
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical researcher with expertise in herbal medicine, drug formulation, neuropharmacology, and medical device design, holding advanced degrees in pharmacy, pharmacology, or biomedical engineering with 3-5 years of specialized experience
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core invention, utilizing standard pharmaceutical development techniques to enhance the original Polygala extract treatment method. The disclosed improvements address known limitations in botanical extract delivery and efficacy through well-established pharmaceutical engineering approaches. These variations demonstrate incremental innovations that would be obvious to a skilled practitioner seeking to optimize the original treatment methodology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,592 |
|---|---|
| Title | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
| Assignee(s) | BioLite Inc. |